F-10: Oncolytics Biotech Seeks to Raise C$150 Million Through Shelf Prospectus

Oncolytics Biotech Inc. has filed a short form base shelf prospectus to offer up to C$150 million in common shares, subscription receipts, warrants, and units over a 25-month period.

Summary

• Oncolytics Biotech Inc. has filed a short form base shelf prospectus to offer securities worth up to C$150 million.
• The securities include common shares, subscription receipts, warrants, and units, which may be offered separately or together.
• The offering will be available for 25 months after the prospectus is validated.
• The specific terms of any offering will be detailed in a prospectus supplement.
• The company's common shares are listed on the Toronto Stock Exchange (ONC) and the Nasdaq Capital Market (ONCY).
• As of July 18, 2024, the closing price of Oncolytics' common shares was C$1.40 on the TSX and US$1.03 on the Nasdaq.
• The company intends to use the proceeds as detailed in a future prospectus supplement.
• The company has issued 1,566,265 common shares since March 31, 2024, through an equity distribution agreement with Canaccord Genuity LLC, at an average price of US$1.10 per share.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document is a standard regulatory filing for a potential capital raise. While it provides financial flexibility, it also highlights the company's ongoing losses and the risks associated with its business.

Positives

• The shelf prospectus provides Oncolytics Biotech with flexibility to raise capital over the next 25 months as needed.
• The company has access to both Canadian and U.S. markets, with listings on the TSX and Nasdaq.

Negatives

• The document indicates that there is no market through which the Subscription Receipts, Warrants or Units may be sold and purchasers may not be able to resell the Subscription Receipts, Warrants or Units purchased under this Prospectus.
• The document indicates that the company has not been profitable since its inception and expects to continue to incur substantial losses as it continues research and development efforts.

Risks

• An investment in the Securities involves a high degree of risk.
• The document outlines various risks including those related to product development, clinical trials, regulatory approvals, intellectual property, reliance on third parties, and market acceptance.
• The company's future performance is subject to various risks and uncertainties, including the success of clinical trials and regulatory approvals.
• The document contains forward-looking statements that are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied.

Future Outlook

The company may offer and issue securities from time to time during the 25-month period that the short form base shelf prospectus remains valid, with the specific terms of any offering to be set forth in the applicable prospectus supplement.

Industry Context

This announcement is typical for biotech companies seeking funding for ongoing research and development. Shelf prospectuses allow companies to access capital markets quickly and efficiently as opportunities arise.

Comparison to Industry Standards

• Many biotech companies, such as Amgen, Gilead Sciences, and Biogen, utilize shelf registrations to maintain financial flexibility.
• The size of the offering (C$150 million) is within the typical range for companies of Oncolytics' size and stage of development.
• The types of securities being offered (common shares, warrants, subscription receipts, and units) are standard instruments used in biotech financing.

Stakeholder Impact

• Shareholders may experience dilution if new common shares are issued.
• The capital raise could provide the company with additional resources to advance its research and development programs, potentially benefiting patients and the medical community.
• Employees may benefit from increased job security and opportunities if the company is successful in raising capital and advancing its pipeline.

Next Steps

• The company will file prospectus supplements to detail the specific terms of any future offerings.
• The company will determine the timing and amount of any securities to be offered under the shelf prospectus.
• Investors should review any applicable prospectus supplement before making an investment decision.

Key Dates

Keywords

Oncolytics Biotech, shelf prospectus, common shares, subscription receipts, warrants, units, capital raise, pelareorep, immunotherapeutic agent, securities